
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines Ltd shows a strong growth outlook driven by its lead asset, Brukinsa, which has established a leading position in the BTK inhibitor market, with projected peak sales reaching approximately $7.1 billion by 2034. The company’s sonrotoclax, touted as the most advanced BCL2 inhibitor, exhibits improved efficacy and safety compared to existing treatments, bolstering expectations for significant additional revenue, estimated at around $3.4 billion. This positive trajectory is further supported by planned physician outreach and competitive contracting strategies, which are anticipated to drive over 40% year-over-year growth, positioning BeOne towards profitable operations and positive free cash flow by 2025.
Bears say
BeOne Medicines Ltd faces a negative outlook primarily due to the possibility of slower-than-expected commercial uptake of its products and potential failures in its pipeline initiatives, which includes the solid tumor initiative and sonrotoclax, that could severely impact financial viability. Moreover, key risks such as significant cash burn without resulting marketable drugs, perceived geopolitical risks associated with the company’s Chinese origin, and challenges in a crowded heme-oncology space could further weaken the company’s competitive positioning. Additionally, any adverse regulatory decisions, unexpected safety signals, or delays in product development and commercialization could negatively affect market potential and future earnings projections.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares